Fecal Microbiota Transplantation for Irritable Bowel Syndrome

Irritable Bowel Syndrome Clinical Trial

Official title:

Efficacy and Safety of Fecal Microbiota Transplantation for Irritable Bowel Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03613545
• Other study ID #: K-2017-078-02
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: August 10, 2018
• Est. completion date: December 31, 2030

Study information

• Verified date: July 2021
• Source: Guangzhou First People's Hospital
• Contact: Hongli Huang, MM
• Phone: 86-13631316718
• Email: honglisums[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Fecal microbiota transplantation (FMT) is a strategy that infuses a fecal suspension containing a healthy donor's microbiota into a patient's gut to restore his/her intestinal microbiome. FMT has a higher cure rate than standard antibiotic treatment for recurrent Clostridium difficile infections,and shows promising results in Inflammatory bowel disease（IBD）.However, few studies have evaluated whether FMT is effective to treat Irritable bowel syndrome(IBS).The investigators propose to determine the efficiency and safety of FMT in patients with Irritable bowel syndrome.

Description:

The present clinical trial aims to re-establish a gut functionality state of intestinal flora through FMT as a therapy for Irritable bowel syndrome(IBS). We established a standard microbiota isolation from donated fresh stool in lab. Then the microbiota is transplanted to the whole colon through a tube. Patients from Guangzhou First People's Hospital in this study will be assigned to receive FMT at least two times according to associated guidelines and follow-up for at least six months. Questionnaires will be used to assess participants at study start and at study completion.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: December 31, 2030
• Est. primary completion date: December 31, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

To be considered eligible for enrolment into the study, subjects must:

• Be able to give written informed consent.

• Males and females aged >18 and <75

• Have IBS as defined by the Rome IV criteria

Exclusion Criteria:

Subjects will be excluded from the study if they meet any of the below criteria:

• pregnant or having a follow-up of less than 6 months;

• unable to give informed consent;

• suffering from other severe disease ,including liver and kidney failure, cancers, intestinal diseases, inflammatory bowel disease, C difficile infection;

• unable to undergo endoscopy.

Related Conditions & MeSH terms

• Fecal Microbiota Transplantation
• Irritable Bowel Syndrome
• Syndrome

Intervention

Procedure:
• fecal microbiota transplantation
200 mL of prepared fecal microbiota suspension from heathy donors' fresh feces was injected into the colon
• Infusion of sham
Infusion of sham

Drug:
• probiotics, antibiotics or antidepressants
Drugs such as probiotics, antibiotics, antidepressants

Locations

Country	Name	City	State
China	Guangzhou First People's Hospital	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Guangzhou First People's Hospital

Country where clinical trial is conducted

China, 

References & Publications (1)

Distrutti E, Monaldi L, Ricci P, Fiorucci S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J Gastroenterol. 2016 Feb 21;22(7):2219-41. doi: 10.3748/wjg.v22.i7.2219. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Irritable Bowel Syndrome assessed by Symptom Severity Score (IBS-SSS)	This questionnaire was used for assessing IBS severity. Scores of five questions were calculated with the Visual Analogue Scale (VAS) scale: the severity of abdominal pain, the frequency of abdominal pain, the severity of abdominal distention, dissatisfaction with bowel habits and interference with quality of life. The scores ranged from 0 to 500, a higher score indicating worse condition :<75 indicated remission; 75-175 indicated mild IBS;176-300 indicated moderate IBS; and > 300 indicated severe IBS .	baseline; one month;three months;six months
Secondary	Change in Irritable Bowel Syndrome assessed by Quality of Life (IBS-QOL) Questionnaire Scores	The IBS-QOL questionnaire consisted of 34 items, covering eight aspects (dysphoria, interference with activity, body image, health worry, food avoidance,social reaction, sexual dysfunction, and relationships). Each item was rated on a 5-point Likert scale(1 = not at all, 5 = a great deal). Total scores were transformed to a 0±100 scale ranging from 0 (maximum quality of life) to 100 (poor quality of life).	baseline; one month;three months;six months
Secondary	Change in Depression and Anxiety assessed by Hamilton Depression Rating Scale (HAMD) and Hamilton Anxiety Rating Scale(HAMA)	The Hamilton Depression Rating Scale (HAMD) and Hamilton Anxiety Rating Scale (HAMA) were used to evaluate the mental and psychological states of patients. HAMD scores were graded as follows: 8-19, mild depression; 20-34, moderate depression; =35, severely depression. HAMA scores were graded as follows: 14-20, mild anxiety; 21-28, moderate anxiety;=29 , severe anxiety.	baseline; one month;three months;six months